Oxidative stress and neurodegeneration: Cause or consequence?;Estrés oxidativo y neurodegeneración: ¿Causa o consecuencia?

Archivos de Neurociencias

Volumn 12, Issue 1, 2007, Pages 45-54

  Pérez, Mariana Angoa ^a,b   Arancibia, Selva Rivas ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Alzheimer's; Amyotrophic lateral sclerosis; Free radicals; Huntington's; Parkinson's; Redox imbalance

Indexed keywords

DNA; PROTEIN; REACTIVE OXYGEN METABOLITE; RNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL ACTIVATION; CELL DEATH; CLINICAL FEATURE; DNA REPAIR; DOPAMINERGIC NERVE CELL; GENE MUTATION; GLIA CELL; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; INFLAMMATION; LEWY BODY; MITOCHONDRION; MOTOR NEURON DISEASE; NEOSTRIATUM; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW;

EID: 34447331666     PISSN: 01874705     EISSN: 01874705     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Smythies J. Redox aspects of signaling by catecholamines and their metabolites. Atioxid Redox Signal 2000;2(3):575-83.
2. McCord JM. Evolution of free radicals and oxidative stress. Am J Med 2000; 108(8):652-9.
3. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443(7113):787-95.
4. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J Neurochem 2006; 97(6)1634-58.
5. Sugaya K, Chou S, Xu S, McKinney M. Indicator of glial activation and brain oxidative stress after intraventricular infusion of an endotoxin. Mol Brain Res 1998;58(1-2):1-9.
6. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 1994;7(6):548-58.
7. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, et al. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005;24:55-99.
8. Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in mammalian cells. FASEB J 1997;11:526-34.
9. Szweda PA, Friguet B, Szweda LI. Proteolysis, free radicals and aging. Free Radic Biol Med 2002;33:29-36.
10. Sitte N, Huber M, Grune T, Ladhoff A, Doecke WD, Von Zglinicki T, et al. Proteasome inhibition by lipofucsin/ceroid during postmitotic aging of fibroblasts. FASEB J 2000;14:1490-8.
11. Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, Morrow CS. Role of multidrug resistance protein 1 (MRP1) and glutathione-S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus memphalan toxicity. J Biol Chem 2001;276:7952-6.
12. Foster KA, Galeffi F, Gerich FJ, Turner DA, Müller M. Optical and pharmacological tools to investigate the role of mitochondria during oxidative stress and neurodegeneration. Prog Neurobiol 2006;79:136-71.
13. Danysz W. Neurotoxicity as a mechanism for neurodegenerative disorders: basic and clinical aspects. Expert Opin Investig Drugs 2001;10(5):985-9.
14. Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 2006;176(1-2):198-215.
15. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurobiol 2005;18:315-21.
16. Zhang J, Fujii S, Wu Z, Hashioka S, Tanaka Y, Shiratsuchi A, et al. Involvement of COX-1 and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced prostaglandin E2 protection by microglía. J Neuroimmunol 2006; 172:112-20.
17. Asanuma M, Miyazaki I. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinine formation. Expert Rev Neurother 2006; (9):1313-25.
18. Asanuma M, Miyazaki I, Ogawa N. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Des 2004;10:695-700.
19. Salmon DP, Thomas RG, Pay MM, Both A, Hofstetter CR, Thal LJ, et al. Alzheimer's disease can be accurately diagnosed in very midly impaired individuals. Neurology 2002;99:1022-8.
20. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001;8:721-38.
21. De Leo ME, Borrello S, Passantino M, Palazzotti B, Mordente A, Daniele A, et al. Oxidative stress and overexpression of manganeso superoxide dismutasa in patients with Alzheimer's disease. Neurosci Lett 1998;250(3):173-6.
22. Bonilla E, Tanji K, Hirano M, Vu TH, DiMAuro S, Schon EA. Mitochondrial involvement in Alzheimer's disease. Biochim Biophys Acta 1999;1410(2):171-82.
23. Moreira PM, Smith MA, Zhu X, Nanomura A, Castellani RJ, Perry G. Oxidative stress and neurodegeneration. Ann N Y Acad Sci 2005;1043:545-52.
24. Liu Z, Sayre LM. Model Studies on the modification of proteins by lipoxidation-derived-2-hydroxyaldehydes. Chem Res Toxicol 2003;16(2):232-41.
25. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17(8):2653-7.
26. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006;8(11-12):2021-37.
27. Shan X, Lin CL. Quantification of oxidized RNAs in Alzheimer's disease. Neurobiol Aging 2006; 27(5):657-62.
28. Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, et al. Oxidative modification of protein in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 2006;27(1):42-53.
29. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics. Eur J Pharmacol 2006;545:39-50.
30. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, et al. The glial glutamate transporter GLT1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem 2001;78:413-16.
31. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease: a double edge sword. Neuron 2002;35:419-32.
32. Ramasamy R, Vannucci SJ, Shi Du Yan S, Herold K, Fang Yang S, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology 2005;15(7):16-28.
33. El Khouri, Hickman SE, Thomas CA, Cao L, Silverstein SC, Like JD. Scavenger receptor-mediated adhesion of microglia to beta amyloid fibrils. Nature 1996;382:716-9.
34. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimer Dis other Demen 2006; 21(3):197-211.
35. Jenner R Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47(6 Suppl 3):S161-70.
36. Jensen PH, Hager J, Nielsen MS, Hojrup P, Gliemann J, Jakes R. Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 1999;274:25481-89.
37. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 2006;70:419-26.
38. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
39. Gal S, Fridkin M, Amit T, Zheng H, Youdim MB. M30, a novel multifunctional protective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J Neural Trnsm Suppl 2006;70:447-56
40. Soto-Otero R, Sanmartin-Suarez C, Sanchelglesias S, Hermida-Ameijeiras A, Sanchez-Sellero I, Mendez-Alvarez E. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to Parkinson's disease. J Biochem Mol Toxicol 2006;20:(5)209-20.
41. Méndez-Alvarez E, Soto-Otero R. Dopamine: a double-edged sword for the human brain. Recent Res Devel Life Sci 2004; 2:217-246.
42. Yim MB, Yim HS, Chock PB, Stadtman ER. Enhanced free radical generation of FALS-associated Cu, Zn-SOD mutants. Neurotox Res 1999;1(2):91-7.
43. Kang JH, Eum WS. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutants. Biochim Biophys Acta 2000;1524(2-3):162-70.
44. Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER. A gain-of-function of an amyotriophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci USA 1996;93(12): 5709:14.
45. Browne SE, Beal MR Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006;8(11-12):2061-73.
46. Goswami A, Dikshit P, Mishra A, Mulherkar S, Nukina N, Jana NR. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun 2006; 342(1):184-90.
47. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 2001;79(6):1246-9.
48. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, et al. Tryptophan metabolism and oxidative stress in patients with Huntington disease. J Neurochem 2005;93(3):611-23.
49. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, et al. Combination therapy using myocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006;1762(3):373-80.
50. Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuro-Psychopharmacol Biol Psychiat 2003;27:303-21.